MedTrace Logo

Transdermal Rotigotine User Surveillance Study

NCT00599339 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2195

Last updated 2018-08-09

Study results available
· View outcomes & findings →

Summary

This study will be conducted in an observational multiple-cohort design aimed at acquiring clinical, treatment, health status, and economic data. Patients with Parkinson's disease (PD) will be enrolled.

Conditions

  • Idiopathic Parkinson Disease

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Czechia
  • Denmark
  • Germany
  • Greece
  • Italy
  • Mexico
  • Romania
  • Slovakia
  • Spain
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00599339 on ClinicalTrials.gov